Advanced Biomed Inc
ADVBHealthcare·Diagnostics & Research·Taiwan·Nano·NASD·Nov 13 • 7:50 AM ET
3.10-0.21 (-6.34%)
2026-11-13 13:54 CET
Market cap
$5.12M
Revenue, TTM
0.00 USD m
Net income, TTM
-0.24 USD m
Free cash flow, TTM
-0.06 USD m
EPS diluted, TTM
-0.08
Price
ADVB against its 20, 50 and 200-day averagesPatternshover a marker to name it
87.2% under the 52-week high of 24.23 on 24 Jul 2026. 52-week low 1.80 on 5 Nov 2026. Last 15 sessions, 119.4% high to low
Volume 5.56× normal · the line is the 50-bar volume average
Setup. RS line 0
CANSLIM 0 of 6 — fails: EPS Growth Qtr Over Qtr: High (>25%); 52-Week High/Low: 0-10% below High; Performance: Year +50%; Institutional Ownership: Over 50%; Average Volume: Over 200K — not on the tape: EPS Growth This Year: High (>25%)
VCP 2 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Relative Volume: Under 1
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 2 of 5 — fails: RSI (14): Not Oversold (>50); 20-Day High/Low: 0-5% below High; 200-Day Simple Moving Average: Price above SMA200
Leaders 0 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; Average Volume: Over 500K; 52-Week High/Low: 0-10% below High
Breakout 1 of 4 — fails: 52-Week High/Low: New High; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 0 of 4 — fails: EPS Growth Qtr Over Qtr: High (>25%); Return on Equity: Over +15% — not on the tape: EPS Growth This Year: High (>25%); EPS Growth Next Year: High (>25%)
Quality 2 of 5 — fails: Return on Equity: Over +15%; Net Profit Margin: High (>20%) — not on the tape: P/E: Under 25
Value 1 of 4 — fails: P/B: Under 2; Return on Equity: Over +15% — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 1 of 4 — fails: Average Volume: Over 500K; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 1 of 4 — fails: Institutional Ownership: Over 30%; 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 0 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200; Average Volume: Over 500K
Profile
ADVB52-week range, 6% of the way up
1.8024.23
Advanced Biomed, Inc. operates as a holding company with interests in developing biochip technologies. It engages in the research & development of microfluidic biochip technologies and provides tumor diagnosis and treatment technology applications. The company was founded by Yi Lu and Steven I-Fang Cheng in 2014 and is headquartered in Tainan, Taiwan.
| Employees | 12 |
|---|---|
| IPO | Mar 06, 2025 |
| Beta | 0.33 |
| ATR, 14d | 0.57 |
| Rel volume | 5.56 |
| Short float | 1.18% |
| Insider own | 42.70% |
| Inst own | 1.55% |
Snapshot
6 groupsValuation
| Index | - |
|---|---|
| Market Cap | $5.12M |
| Enterprise Value | 5.14M |
| Income | -0.24M |
| Sales | 0.00M |
| Book / share | 0.23 |
| Cash / share | 0.01 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 12 |
| IPO | Mar 06, 2025 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | - |
| Price / book | 13.29 |
| Price / cash | 512.30 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | - |
| Quick Ratio | 9.33 |
| Current Ratio | 9.33 |
| Debt / equity | 0.08 |
| Long-term debt / equity | 0.00 |
| Options and short | No / Yes |
Earnings
Ownership
| Insiders own | 42.70% |
|---|---|
| Insider trades | 0.00% |
| Institutions own | 1.55% |
| Institution trades | 43.40% |
| Return on assets | -60.71% |
| Return on equity | -78.78% |
| Return on capital | -61.60% |
| Gross Margin | -110.23% |
| Operating margin | -5535.26% |
| Profit Margin | -5880.80% |
| 20-day average | 12.35% |
| 50-day average | -39.47% |
| 200-day average | -45.87% |
Technical
| Shares out | 1.65M |
|---|---|
| Shares floating | 0.95M |
| Short / float | 1.18% |
| Short ratio | 0.11 |
| Short interest | 0.01M |
| 52-week high | 24.23 -87.2% |
| 52-week low | 1.80 +72.2% |
| Volatility | 24.43% 20.81% |
| Average range | 0.57 |
| Strength index | 45.02 |
| Market sensitivity | 0.33 |
| Relative volume | 5.56 |
| Avg Volume | 103.51K |
| Volume | 28,768 |
Performance
| Perf Week | 56.57% |
|---|---|
| Perf Month | -36.48% |
| Perf Quarter | -62.33% |
| Perf Half Y | -29.55% |
| Perf YTD | -46.88% |
| Perf Year | -65.41% |
| Perf 3Y | - |
| Perf 5Y | - |
| Perf 10Y | - |
| Recommendation | - |
| Target Price | - |
| Prev Close | 3.31 |
| Price | 3.10 |
| Change % | -6.34% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| BIAF | BioAffinity Technologies Inc | 4.26M |
| PRPO | Precipio Inc | 41.69M |
| MDXH | MDxHealth SA | 13.28M |
| BNR | Burning Rock Biotech Ltd ADR | 117.17M |
| IMDX | Insight Molecular Diagnostics Inc | 75.59M |
| QTRX | Quanterix Corp | 136.74M |
| XGN | Exagen Inc | 112.51M |
| BNGO | Bionano Genomics Inc | 14.40M |
| CODX | Co-Diagnostics Inc | 2.62M |
| LUCD | Lucid Diagnostics Inc | 83.23M |
Quarterly earnings
actual against estimate
The earnings feed came back with no quarters.
Annual earnings
The earnings feed came back with no years.
Quarterly results
2026Q4 revenue 0.00, from 0.00 a year earlier
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type.
No estimate revisions.
Estimate history
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| EPS per share | -0.06 | -0.132 | -0.112 | -0.081 | -0.099 | -0.189 |
| Sales USD millions | 0 | 0 | 0 | 0 | 0 | 0 |
| Shares million shares | 1 | 1 | 1 | 1 | 1 | 2 |
| Metric | Q2 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | Q4 '26 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.004 | -0.008 | -0.026 | -0.039 | -0.021 | -0.012 | 0.204 | -0.012 | -0.26 |
| Sales USD millions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shares million shares | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
Income statement, annual
| Metric | TTM | 2026FY6/30/2026 | 2025FY6/30/2025 | 2024FY6/30/2024 | 2023FY6/30/2023 | 2022FY6/30/2022 | 2021FY6/30/2021 |
|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | - | - | 0.00-100.0% | 0.010.0% | 0.01 | 0.00 | 0.00 |
| Gross Profit | - | - | 0.00 | -0.01 | -0.01 | -0.00 | -0.00 |
| Selling, General and Administrative Excl. Other | 0.23 | 0.20+566.7% | 0.03-57.1% | 0.07-22.2% | 0.09+12.5% | 0.08+33.3% | 0.06 |
| Research and Development | - | - | 0.030.0% | 0.03-40.0% | 0.05-16.7% | 0.060.0% | 0.06 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -0.22 | -0.20 | -0.03 | -0.08 | -0.10 | -0.08 | -0.06 |
| Interest Expense | - | 0.00 | - | - | 0.00 | 0.00 | 0.00 |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.06 | 0.00 |
| Net Income Before Taxes | -0.20 | -0.20 | -0.03 | -0.09 | -0.12 | -0.14 | -0.06 |
| Income Taxes | -0.00 | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -0.20 | -0.20 | -0.03 | -0.09 | -0.12 | -0.14 | -0.06 |
| Net Income From Continuing Operations | -0.20 | -0.20 | -0.03 | -0.09 | -0.12 | -0.14 | -0.06 |
| Net Income | -0.24 | -0.24 | -0.10 | -0.09 | -0.12 | -0.14 | -0.06 |
| EPS (Recurring) per share | -0.14 | -0.19 | -0.10 | -0.08 | -0.11 | -0.09 | -0.06 |
| EPS (Basic, Before Extraordinaries) per share | -0.08 | -0.19 | -0.10 | -0.08 | -0.11 | -0.13 | -0.06 |
| EPS (Diluted) per share | -0.08 | -0.19 | -0.10 | -0.08 | -0.11 | -0.13 | -0.06 |
| EBITDA | -0.22 | -0.20 | -0.03 | -0.07 | -0.09 | -0.08 | -0.06 |
| Non-Operating Income (Expense) | 0.24 | -0.00 | 0.00 | -0.01 | -0.02 | -0.00 | -0.00 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | - | 0.04 | 0.00 | - | - | - | - |
| Price To Sales Ratio ratio | 1,902.77 | 1,416.32 | - | - | - | - | - |
| Operating Margin % | -5,535.26 | -4,883.59 | - | - | - | - | - |
| Net Margin % | -5,880.80 | -5,749.13 | - | - | - | - | - |
| Shares Outstanding million shares | 1.65 | 1.65+52.8% | 1.080.0% | 1.080.0% | 1.080.0% | 1.080.0% | 1.08 |
| Market Capitalization | 5.47 | 5.47-63.9% | 15.15-1.4% | 15.36 | - | - | - |
Income statement, quarterly
| Metric | 2026Q46/30/2026 | 2026Q33/31/2026 | 2026Q212/31/2025 | 2026Q19/30/2025 | 2025Q46/30/2025 | 2025Q33/31/2025 | 2025Q212/31/2024 | 2025Q19/30/2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Selling, General and Administrative Excl. Other | 0.18+350.0% | 0.020.0% | 0.010.0% | 0.02+100.0% | 0.04 | 0.02 | 0.01-50.0% | 0.010.0% |
| Research and Development | - | 0.010.0% | 0.010.0% | 0.010.0% | 0.01 | 0.01 | 0.010.0% | 0.010.0% |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -0.18 | -0.02 | -0.01 | -0.02 | -0.04 | -0.02 | -0.02 | -0.02 |
| Interest Expense | 0.00 | 0.00 | - | - | - | 0.00 | 0.00 | 0.00 |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Before Taxes | -0.40 | -0.02 | 0.23 | -0.01 | -0.02 | -0.04 | -0.03 | -0.01 |
| Income Taxes | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -0.40 | -0.02 | 0.23 | -0.01 | -0.02 | -0.04 | -0.03 | -0.01 |
| Net Income From Continuing Operations | -0.40 | -0.02 | 0.23 | -0.01 | -0.02 | -0.04 | -0.03 | -0.01 |
| Net Income | -0.43 | -0.02 | 0.22 | -0.01 | -0.02 | -0.04 | -0.03 | -0.01 |
| EPS (Recurring) per share | -0.26 | -0.01 | 0.20 | -0.01 | -0.02 | -0.04 | -0.03 | -0.01 |
| EPS (Basic, Before Extraordinaries) per share | -0.26 | -0.01 | 0.20 | -0.01 | -0.02 | -0.04 | -0.03 | -0.01 |
| EPS (Diluted) per share | -0.26 | -0.01 | 0.20 | -0.01 | -0.02 | -0.04 | -0.03 | -0.01 |
| EBITDA | -0.18 | -0.02 | -0.01 | -0.02 | -0.04 | -0.02 | -0.01 | -0.01 |
| Non-Operating Income (Expense) | -0.00-100.0% | 0.00 | 0.24 | 0.00-100.0% | 0.02 | -0.02 | -0.01-150.0% | 0.01 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 0.04 | - | - | - | - | - | - | - |
| Price To Earnings Ratio ratio statement ratio, not the snapshot | - | 34.44 | 44.08 | - | - | - | - | - |
| Price To Sales Ratio ratio | 1,902.77 | - | - | - | - | - | - | - |
| Operating Margin % | -4,377.96 | - | - | - | - | - | - | - |
| Net Margin % | -10,650.73 | - | - | - | - | - | - | - |
| Shares Outstanding million shares | 1.65+52.8% | 1.38+27.8% | 1.080.0% | 1.080.0% | 1.08 | 1.08 | 1.080.0% | 1.080.0% |
| Market Capitalization | 5.47-63.9% | 6.22-92.7% | 6.31-92.7% | 9.70 | 15.15 | 84.83 | 86.56 | - |
Balance sheet, annual
| Metric | 2026FY6/30/2026 | 2025FY6/30/2025 | 2024FY6/30/2024 | 2023FY6/30/2023 | 2022FY6/30/2022 | 2021FY6/30/2021 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 0.01 | 0.00-100.0% | 0.080.0% | 0.08-50.0% | 0.16 | 0.00 |
| Short Term Receivables | 0.42 | 0.00-100.0% | 0.01 | 0.00-100.0% | 0.01 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00-100.0% | 0.77+7600.0% | 0.01 | 0.00 | 0.00-100.0% | 0.03 |
| Total Current Assets | 0.43-44.2% | 0.77+755.6% | 0.090.0% | 0.09-47.1% | 0.17+466.7% | 0.03 |
| Net Property, Plant & Equipment | 0.00 | 0.00-100.0% | 0.02-33.3% | 0.03-25.0% | 0.04 | 0.00 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 0.00 | 0.00 | 0.00-100.0% | 0.010.0% | 0.01 | 0.00 |
| Deferred Tax Assets | 0.00 | 0.00 | - | - | - | - |
| Other Assets | 0.00-100.0% | 0.020.0% | 0.020.0% | 0.02 | 0.00 | 0.00 |
| Total Assets | 0.43-44.9% | 0.78+457.1% | 0.14-6.7% | 0.15-34.8% | 0.23+475.0% | 0.04 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.03 | 0.00 | 0.00-100.0% | 0.010.0% | 0.01 | 0.00 |
| Accounts Payable | 0.00 | 0.00-100.0% | 0.020.0% | 0.02-33.3% | 0.03 | 0.00 |
| Other Current Liabilities | 0.01-98.5% | 0.66+1000.0% | 0.06-25.0% | 0.08+14.3% | 0.07 | 0.00 |
| Total Current Liabilities | 0.05-92.4% | 0.66+725.0% | 0.08-27.3% | 0.11+10.0% | 0.10 | 0.00 |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.01 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 0.05-92.4% | 0.66+633.3% | 0.09-18.2% | 0.110.0% | 0.11 | 0.00 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 0.39+225.0% | 0.12+140.0% | 0.05+25.0% | 0.04-66.7% | 0.12+200.0% | 0.04 |
| Total Shareholders Equity | 0.39+225.0% | 0.12+140.0% | 0.05+25.0% | 0.04-66.7% | 0.12+200.0% | 0.04 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 0.39+225.0% | 0.12+140.0% | 0.05+25.0% | 0.04-66.7% | 0.12+200.0% | 0.04 |
| Total Liabilities & Stockholders Equity | 0.43-44.9% | 0.78+457.1% | 0.14-6.7% | 0.15-34.8% | 0.23+475.0% | 0.04 |
| Book Value Per Share per share | 0.23+109.1% | 0.11+120.0% | 0.05+25.0% | 0.04-63.6% | 0.11+266.7% | 0.03 |
| Tangible Book Value Per Share per share | 0.23+109.1% | 0.11+175.0% | 0.04+33.3% | 0.03-70.0% | 0.10+233.3% | 0.03 |
| Full-Time Employees people | 12-61.3% | 31-22.5% | 400.0% | 40 | - | - |
| Price to Book Ratio ratio | 14.19 | 127.25 | 123.52 | - | - | - |
| Return on Assets % | -61.64 | -7.36 | -61.30 | -65.07 | -108.76 | - |
| Return on Equity % | -79.99 | -39.75 | -187.60 | -152.52 | -186.83 | - |
| Return on Invested Capital % | -61.36 | -83.60 | -164.13 | -285.77 | -113.73 | -183.80 |
| Quick Ratio ratio | 9.33 | 1.16 | 1.12 | 0.85 | 1.67 | 32.22 |
| Current Ratio ratio | 9.33 | 1.16 | 1.12 | 0.85 | 1.67 | 32.22 |
Cash flow, annual
| Metric | TTM | 2026FY6/30/2026 | 2025FY6/30/2025 | 2024FY6/30/2024 | 2023FY6/30/2023 | 2022FY6/30/2022 | 2021FY6/30/2021 |
|---|---|---|---|---|---|---|---|
| Net Income | 0.21 | 0.22 | -0.10 | -0.09 | -0.12 | -0.14 | -0.06 |
| Depreciation | - | - | 0.010.0% | 0.010.0% | 0.01 | 0.00 | 0.00 |
| Other Funds (Non Cash) | -0.28 | -0.28 | -0.04 | 0.00 | 0.00-100.0% | 0.06 | 0.00 |
| Funds from Operations | -0.07 | -0.07 | -0.14 | -0.07 | -0.10 | -0.08 | -0.06 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 0.00 | 0.00 | -0.04-500.0% | 0.010.0% | 0.01-80.0% | 0.050.0% | 0.05 |
| Cash from Operating Activities | -0.06 | -0.06 | -0.18 | -0.07 | -0.10 | -0.03 | -0.02 |
| Capital Expenditures | -0.00 | 0.00 | 0.00 | -0.00 | -0.01 | -0.05 | -0.00 |
| Net Assets From Acquisitions | -0.08 | -0.08 | 0.00 | 0.00 | -0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.01 | 0.00 |
| Cash from Investing Activities | -0.08 | -0.08 | -0.00 | -0.00 | -0.01 | -0.04 | -0.00 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 0.01 | 0.01-94.1% | 0.17 | -0.00-100.0% | 0.01-95.5% | 0.22+1000.0% | 0.02 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 0.01 | 0.01-94.1% | 0.17 | -0.00-100.0% | 0.01-95.5% | 0.22+1000.0% | 0.02 |
| Proceedsfrom Stock Options | 0.01 | 0.01-94.1% | 0.17 | -0.00-100.0% | 0.01-95.5% | 0.22+1000.0% | 0.02 |
| Issuance or Reduction of Debt, Net | 0.03 | 0.03+200.0% | 0.01-80.0% | 0.05 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.03 | 0.03+200.0% | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.03 | 0.03+200.0% | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.02 | 0.02+100.0% | 0.010.0% | 0.01 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 0.06 | 0.06-66.7% | 0.18+200.0% | 0.06+500.0% | 0.01-95.5% | 0.22+1000.0% | 0.02 |
| Exchange Rate Effect | -0.00 | -0.00-100.0% | 0.010.0% | 0.01-50.0% | 0.020.0% | 0.02 | -0.01 |
| Net Change in Cash | -0.08 | -0.08-900.0% | 0.01 | -0.00 | -0.07-141.2% | 0.17 | 0.00 |
| Free Cash Flow | -0.06 | -0.06 | -0.18 | -0.07 | -0.10 | -0.06 | -0.02 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Taxes & Investment Tax Credit | - | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q46/30/2026 | 2026Q33/31/2026 | 2026Q212/31/2025 | 2026Q19/30/2025 | 2025Q46/30/2025 | 2025Q33/31/2025 | 2025Q212/31/2024 | 2025Q19/30/2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 0.01-90.0% | 0.08-50.0% | 0.080.0% | 0.09+12.5% | 0.10 | 0.16 | 0.08-11.1% | 0.080.0% |
| Short Term Receivables | 0.42+4100.0% | 0.00-100.0% | 0.00-100.0% | 0.010.0% | 0.01 | 0.01 | 0.010.0% | 0.010.0% |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00-100.0% | 0.24+242.9% | 0.26+2500.0% | 0.09+800.0% | 0.10 | 0.07 | 0.010.0% | 0.01 |
| Total Current Assets | 0.43+104.8% | 0.33+43.5% | 0.34+240.0% | 0.19+90.0% | 0.21 | 0.23 | 0.100.0% | 0.10+11.1% |
| Net Property, Plant & Equipment | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 0.01-50.0% | 0.01 | 0.02 | 0.02-33.3% | 0.02-33.3% |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 0.00 | - | - | - | 0.00 | 0.00 | 0.00-100.0% | 0.00-100.0% |
| Deferred Tax Assets | 0.00 | - | - | - | - | - | - | - |
| Other Assets | 0.00 | 7E-05 | 3E-05-99.9% | 0.00-100.0% | 0.00 | 0.00 | 0.020.0% | 0.020.0% |
| Total Assets | 0.43+95.5% | 0.33+32.0% | 0.35+150.0% | 0.20+42.9% | 0.22 | 0.25 | 0.14-12.5% | 0.140.0% |
| Short Term Debt Incl. Current Port. of LT Debt | 0.03-25.0% | 0.02 | 0.02+100.0% | 0.05 | 0.04 | 0.00 | 0.01 | 0.00-100.0% |
| Accounts Payable | 0.00-100.0% | 0.01-50.0% | 0.01-50.0% | 0.020.0% | 0.02 | 0.02 | 0.020.0% | 0.020.0% |
| Income Tax Payable | - | 0.00 | 0.00 | - | - | - | - | - |
| Other Current Liabilities | 0.01-75.0% | 0.01-90.0% | 0.01-88.9% | 0.03-62.5% | 0.04 | 0.10 | 0.09-30.8% | 0.08-11.1% |
| Total Current Liabilities | 0.05-50.0% | 0.04-66.7% | 0.04-66.7% | 0.100.0% | 0.10 | 0.12 | 0.12-20.0% | 0.10-9.1% |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 0.05-50.0% | 0.04-69.2% | 0.04-66.7% | 0.110.0% | 0.10 | 0.13 | 0.12-20.0% | 0.110.0% |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 0.39+225.0% | 0.29+141.7% | 0.30+1400.0% | 0.10+233.3% | 0.12 | 0.12 | 0.02+100.0% | 0.03+50.0% |
| Total Shareholders Equity | 0.39+225.0% | 0.29+141.7% | 0.30+1400.0% | 0.10+233.3% | 0.12 | 0.12 | 0.02+100.0% | 0.03+50.0% |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 0.39+225.0% | 0.29+141.7% | 0.30+1400.0% | 0.10+233.3% | 0.12 | 0.12 | 0.02+100.0% | 0.03+50.0% |
| Total Liabilities & Stockholders Equity | 0.43+95.5% | 0.33+32.0% | 0.35+150.0% | 0.20+42.9% | 0.22 | 0.25 | 0.14-12.5% | 0.140.0% |
| Book Value Per Share per share | 0.23+109.1% | 0.21+90.9% | 0.28+1300.0% | 0.09+200.0% | 0.11 | 0.11 | 0.02+100.0% | 0.03+50.0% |
| Tangible Book Value Per Share per share | 0.23+109.1% | 0.21+90.9% | 0.28+1300.0% | 0.09+200.0% | 0.11 | 0.11 | 0.02 | 0.03+50.0% |
| Full-Time Employees people | 12-61.3% | - | - | - | 31 | - | - | - |
| Price to Book Ratio ratio | 14.19 | 16.35 | 20.93 | 98.38 | 127.25 | 681.98 | 4,584.53 | - |
| Return on Assets % | -60.71 | 59.90 | 61.27 | -61.12 | - | - | - | - |
| Return on Equity % | -78.78 | 84.61 | 92.23 | -158.93 | - | - | - | - |
| Return on Invested Capital % | -111.57 | -5.36 | 72.34 | -12.32 | -18.31 | -33.47 | -136.29 | -22.33 |
| Quick Ratio ratio | 9.33 | 7.38 | 8.56 | 1.92 | 2.09 | 1.88 | 0.82 | 0.95 |
| Current Ratio ratio | 9.33 | 7.38 | 8.56 | 1.92 | 2.09 | 1.88 | 0.82 | 0.95 |
Cash flow, quarterly
| Metric | 2026Q46/30/2026 | 2026Q33/31/2026 | 2026Q212/31/2025 | 2026Q19/30/2025 | 2025Q46/30/2025 | 2025Q33/31/2025 | 2025Q212/31/2024 | 2025Q19/30/2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income | 0.01 | -0.02 | 0.23 | -0.01 | -0.03 | -0.04 | -0.03 | -0.01 |
| Depreciation | - | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Funds (Non Cash) | -0.02 | 0.01 | -0.27 | 0.00 | 0.00 | 0.00 | -0.00 | 0.00 |
| Funds from Operations | -0.01 | -0.01 | -0.04 | -0.01 | -0.02 | -0.04 | -0.03 | -0.01 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -0.01 | 0.01 | 0.02 | -0.01 | -0.03 | -0.06 | -0.00 | 0.00 |
| Cash from Operating Activities | -0.02 | -0.01 | -0.02 | -0.02 | -0.06 | -0.10 | -0.03 | -0.00 |
| Capital Expenditures | 0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 | -0.00 |
| Net Assets From Acquisitions | -0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -0.08 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 | -0.00 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 0.00-100.0% | 0.01-94.1% | 0.00 | 0.00 | 0.01 | 0.17 | -0.00 | -0.00 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 0.00-100.0% | 0.01-94.1% | 0.00 | 0.00 | 0.01 | 0.17 | -0.00 | -0.00 |
| Proceedsfrom Stock Options | 0.00-100.0% | 0.01-94.1% | 0.00 | 0.00 | 0.01 | 0.17 | -0.00 | -0.00 |
| Issuance or Reduction of Debt, Net | 0.03+200.0% | 0.00 | -0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.03+200.0% | 0.00 | -0.01 | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.030.0% | -0.00 | -0.01 | 0.02 | 0.03 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | -0.00 | 0.00 | -0.02 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | -0.00-100.0% | 0.02+100.0% | 0.00-100.0% | -0.03 | 0.01 | 0.01-50.0% | 0.010.0% |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 0.03 | 0.01-94.4% | 0.010.0% | 0.010.0% | -0.01 | 0.18 | 0.01-50.0% | 0.010.0% |
| Exchange Rate Effect | -0.00 | -0.00 | 0.010.0% | -0.00 | 0.00 | 0.00 | 0.01 | -0.01-200.0% |
| Net Change in Cash | -0.07 | 0.00-100.0% | -0.00 | -0.01 | -0.07 | 0.08 | 0.00-100.0% | 0.00 |
| Free Cash Flow | -0.02 | -0.01 | -0.02 | -0.02 | -0.06 | -0.10 | -0.03 | -0.00 |
Revenue breakdown
USD millions, so a column adds up to the income statement. Share is of the latest year in that split. The change is versus the older year shown, not TTM.
| Name | 2026 | 2026 share |
|---|---|---|
| Services-Medical Laboratories | 0.13 | 100.0% |
| Total | 0.13 | 100.0% |
| Name | 2026 | 2026 share |
|---|---|---|
| United States | 0.13 | 100.0% |
| Total | 0.13 | 100.0% |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 1.18% | 0.0M | 1.0M | 117.96K |
| 2026-10-15 | 1.03% | 0.0M | 1.0M | 1.72M |
| 2026-09-30 | 2.55% | 0.0M | 0.7M | 1.75M |
| 2026-09-15 | 1.33% | 0.0M | 0.7M | 1.77M |
| 2026-08-31 | 2.21% | 0.0M | 0.7M | 1.73M |
| 2026-08-14 | 5.05% | 0.0M | 0.7M | 1.72M |
| 2026-07-31 | 10.22% | 0.1M | 0.6M | 1.78M |
| 2026-07-15 | 1.89% | 0.0M | 0.6M | 124.84K |
| 2026-06-30 | 4.40% | 0.0M | 0.4M | 428.41K |
| 2026-06-15 | 1.25% | 0.0M | 0.7M | 448.29K |
| 2026-05-29 | 0.34% | 0.0M | 0.6M | 555.99K |
| 2026-05-15 | 0.64% | 0.0M | 0.6M | 576.64K |
| 2026-04-30 | 2.31% | 0.0M | 0.6M | 487.42K |
| 2026-04-15 | 13.29% | 0.0M | 0.4M | 487.59K |
| 2026-03-31 | 7.08% | 0.0M | 0.4M | 169.85K |
| 2026-03-13 | 3.47% | 0.0M | 0.4M | 140.31K |
| 2026-02-27 | 6.14% | 0.0M | 0.4M | 52.12K |
| 2026-02-13 | 0.34% | 0.0M | 1.1M | 26.66K |
| 2026-01-30 | 1.51% | 0.0M | 0.3M | 29.98K |
| 2026-01-15 | 4.97% | 0.0M | 0.2M | 61.73K |
Option chain
Expiry 2026-11-13 · underlying 3.10, quoted 13 Nov 07:50 ET · ATM -
Option quotes -. A date on a row is older than the last session (12 Nov). 0 rows.
Implied move — the ATM straddle is not quoted.
Put/call open interest — no calls · Put/call volume — no calls
IV change is points against the prior close.
| Type | Strike | Money | Bid | Ask | Last | Chg | IV | Open int | Volume | Last size | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No option chain for this symbol. | |||||||||||||
Latest SEC filings
30 of 98AllAll annual, quarterly, and current reportsInsider equity awards, transactions, and ownership (Section 16 Reports)Beneficial ownership reportsExempt offeringsRegistration statements and prospectusesFiling review correspondenceSEC orders and noticesProxy materialsTender offers and going private transactionsTrust indenture filings
10-Q filed 2026-11-12, period ended 2026-09-30. 10-K filed 2026-10-13, period ended 2026-06-30. ADVB on EDGAR
page 1 of 4Next →
| Filed | Form | Description | Period | Document |
|---|---|---|---|---|
| 2026-11-12 | 10-Q | All annual, quarterly, and current reports | 2026-09-30 | 0001213900-26-118899 index |
| 2026-10-13 | 10-K | All annual, quarterly, and current reports | 2026-06-30 | 0001213900-26-109029 index |
| 2026-09-28 | NT 10-K | All annual, quarterly, and current reports | 2026-06-30 | 0001213900-26-104071 index |
| 2026-09-22 | SCHEDULE 13G | Beneficial ownership reports | no report period | 0002155122-26-000001 index |
| 2026-08-20 | SCHEDULE 13G/A | Beneficial ownership reports | no report period | 0001079973-26-001160 index |
| 2026-08-20 | SCHEDULE 13G | Beneficial ownership reports | no report period | 0001079973-26-001158 index |
| 2026-07-20 | RW | Registration statements and prospectuses | no report period | 0001213900-26-079677 index |
| 2026-07-17 | 8-K | All annual, quarterly, and current reports | 2026-07-14 | 0001213900-26-079233 index |
| 2026-07-01 | 8-K | All annual, quarterly, and current reports | 2026-06-30 | 0001213900-26-074306 index |
| 2026-06-30 | 8-K | All annual, quarterly, and current reports | 2026-06-30 | 0001213900-26-073735 index |
| 2026-06-04 | DEF 14A | Proxy materials | 2026-06-30 | 0001213900-26-065017 index |
| 2026-05-15 | 10-Q | All annual, quarterly, and current reports | 2026-03-31 | 0001213900-26-057226 index |
| 2026-05-01 | 8-K | All annual, quarterly, and current reports | 2026-04-28 | 0001213900-26-051028 index |
| 2026-04-14 | 8-K | All annual, quarterly, and current reports | 2026-04-13 | 0001213900-26-043557 index |
| 2026-04-03 | 8-K | All annual, quarterly, and current reports | 2026-04-02 | 0001213900-26-040030 index |
| 2026-03-30 | 8-K | All annual, quarterly, and current reports | 2026-03-25 | 0001213900-26-036424 index |
| 2026-03-16 | 8-K | All annual, quarterly, and current reports | 2026-03-12 | 0001213900-26-028330 index |
| 2026-02-26 | 8-K | All annual, quarterly, and current reports | 2026-02-20 | 0001213900-26-020807 index |
| 2026-02-13 | 10-Q | All annual, quarterly, and current reports | 2025-12-31 | 0001213900-26-016458 index |
| 2026-02-10 | 8-K/A | All annual, quarterly, and current reports | 2025-06-06 | 0001213900-26-014247 index |
| 2026-02-02 | 8-K | All annual, quarterly, and current reports | 2026-01-28 | 0001213900-26-010809 index |
| 2026-01-27 | 8-K | All annual, quarterly, and current reports | 2026-01-26 | 0001213900-26-008254 index |
| 2026-01-23 | DEF 14C | Proxy materials | 2026-01-23 | 0001213900-26-007188 index |
| 2026-01-21 | 8-K | All annual, quarterly, and current reports | 2026-01-16 | 0001213900-26-006281 index |
| 2026-01-12 | PRE 14C | Proxy materials | 2026-01-12 | 0001213900-26-003378 index |
| 2025-12-30 | 8-K | All annual, quarterly, and current reports | 2025-12-23 | 0001213900-25-126584 index |
| 2025-11-19 | 10-Q | All annual, quarterly, and current reports | 2025-09-30 | 0001213900-25-112602 index |
| 2025-11-14 | NT 10-Q | All annual, quarterly, and current reports | 2025-09-30 | 0001213900-25-110809 index |
| 2025-10-08 | 10-K | All annual, quarterly, and current reports | 2025-06-30 | 0001213900-25-097465 index |
| 2025-09-30 | NT 10-K | All annual, quarterly, and current reports | 2025-06-30 | 0001213900-25-093917 index |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| JANE STREET GROUP, LLC | 2.91% |
| GEODE CAPITAL MANAGEMENT, LLC | 1.22% |
| RENAISSANCE TECHNOLOGIES LLC | 0.64% |
| UBS Group AG | 0.27% |
| VALLEY NATIONAL ADVISERS INC | 0.06% |
| Caitong International Asset Management Co., Ltd | 0.00% |
| JPMORGAN CHASE & CO | 0.00% |
Funds
| Fund | % owned |
|---|---|
| Fidelity Nasdaq Composite Index Fund | 1.34% |
OakChart. ADVB. Cached 15 minutes. Terms
Some panels did not load: ratings, insider, news.